
CRISPR Therapeutics (NASDAQ:CRSP) is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY.
CEO Sam Kulkarni said during a Jefferies fireside chat that the company’s CTX310, zugo-cel and CTX611 programs could potentially enter late-stage trials within about a year. He also said CRISPR Therapeutics has more than $2 billion on its balance sheet and is positioned to fund multiple Phase III studies itself.
CTX310 Data and Development Plans
Executives discussed recent data on CTX310, a one-time treatment designed to target ANGPTL3 for lipid reduction. Jefferies analyst Maury Raycroft said the severe hypertriglyceridemia study showed a 63% mean reduction in triglycerides at day 30, alongside reductions in LDL and ApoB.
Chief Medical Officer Naimish Patel said eight of 10 patients had triglyceride levels below 500 by day 28. He described the reduction as comparable in size to results reported for APOC3-targeting therapies, while noting that companies present data differently. He also pointed to reductions in other lipids associated with cardiovascular risk as a potential differentiator.
Asked about one patient who did not respond, Patel said the company had not identified a specific explanation. He said additional patients had been dosed across other study cohorts and that CRISPR Therapeutics had not seen another patient quite like that one.
Executives said more data are expected on glucose control and liver fat. Patel said the company had not seen a glucose-control signal and hoped to provide further HbA1c data in the future.
Kulkarni said the company has not set a timeline for a Phase III trial. He said an FDA meeting associated with CTX310’s regenerative medicine advanced therapy designations could provide an opportunity to discuss trial design, with severe hypertriglyceridemia the first area of focus. Mixed dyslipidemia and homozygous familial hypercholesterolemia are also possible late-stage indications, he said.
Zugo-cel and CTX611 Updates
For zugo-cel, an investigational allogeneic CAR T therapy targeting CD19, Patel said six of seven patients in a scleroderma cohort had an early CRISS-25 response. The two patients who had passed six months achieved CRISS-50 responses, he added.
Patel said three patients in the cohort had interstitial lung disease at baseline and that none had experienced a continued decline in lung function. The company will continue to follow patients for potential improvement, he said. After some patients showed limited cell expansion, CRISPR Therapeutics decided to increase the dose.
In the CTX611 program, which targets Factor XI and is partnered with Sirius, Kulkarni said enrollment had concluded in a Phase II study of more than 400 patients. The company expects top-line data by year-end.
The study is assessing whether the treatment can reduce venous thromboembolism events following total knee replacement. Executives said they hope the therapy can provide anticoagulation without an increase in bleeding and potentially be administered once every six months. Those outcomes remain to be established in the study.
CASGEVY and Upcoming Catalysts
Kulkarni said CRISPR Therapeutics is pleased with demand for CASGEVY, its commercial product partnered with Vertex. He said the product reached close to a $100 million revenue run rate in the prior quarter, while noting Vertex had discussed potential seasonality.
The CEO also identified continuing CTX310 and zugo-cel data, the CTX611 Phase II readout, and potential early data next year from CTX340 in refractory hypertension and the company’s alpha-1 antitrypsin program as catalysts for investors.
About CRISPR Therapeutics (NASDAQ:CRSP)
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
